 Women invited to participate in this study must be post-menopausal and be 18 years of age or older. The study is being performed on a total of 100 individuals. Of this group, 75 will be in the Treatment Groups using FulvestrantAnastrozole with our without bevacizumab and 25 will be in the Best Supportive Care groups receiving no treatment or just bevacizumab at the University of Pittsburgh Medical Center. 